Free tool
FAERS Monitor: Teflaro
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 200327 or its brand name (Teflaro, Ceftaroline Fosamil). Reports on generic versions are filed under their own applications.
Reports
839
Serious
679
81% of reports
Hospitalization
325
Death reported
154
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use141
- neutropenia77
- drug ineffective64
- acute kidney injury52
- death48
- rash46
- agranulocytosis40
- thrombocytopenia37
- pyrexia34
- drug reaction with eosinophilia and systemic symptoms33
- renal failure31
- pruritus29
- toxic epidermal necrolysis27
- eosinophilia26
- staphylococcal infection24
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 15 |
| 2012 | 29 |
| 2013 | 53 |
| 2014 | 71 |
| 2015 | 37 |
| 2016 | 49 |
| 2017 | 30 |
| 2018 | 45 |
| 2019 | 53 |
| 2020 | 42 |
| 2021 | 59 |
| 2022 | 34 |
| 2023 | 62 |
| 2024 | 85 |
| 2025 | 78 |
| 2026 | 97 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,320 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| agranulocytosisSignal | 40 | 54.1 | 39.9 | 2,028 |
| toxic epidermal necrolysisSignal | 27 | 44.6 | 30.8 | 1,108 |
| eosinophiliaSignal | 26 | 37.3 | 25.5 | 881 |
| drug reaction with eosinophilia and systemic symptomsSignal | 33 | 32.2 | 23.0 | 966 |
| staphylococcal infectionSignal | 24 | 18.2 | 12.3 | 375 |
| neutropeniaSignal | 77 | 14.2 | 11.5 | 938 |
| acute kidney injurySignal | 52 | 8.5 | 6.5 | 340 |
| thrombocytopeniaSignal | 37 | 8.3 | 6.1 | 231 |
| renal failureSignal | 31 | 5.9 | 4.1 | 121 |
| off label useSignal | 141 | 4.0 | 3.5 | 333 |
| rashSignal | 46 | 2.6 | 2.0 | 46 |
| pyrexiaSignal | 34 | 2.5 | 1.8 | 29 |
| pruritus | 29 | 1.9 | 1.3 | 12 |
| death | 48 | 1.4 | 1.1 | 5 |
| drug ineffective | 64 | 1.2 | 1.0 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.